Last reviewed 2026-04-23 · How we verify

AEGR-733 and atorvastatin

Aegerion Pharmaceuticals, Inc. · Phase 2 active Small molecule

AEGR-733 and atorvastatin is a MTP inhibitor, HMG-CoA reductase inhibitor Small molecule drug developed by Aegerion Pharmaceuticals, Inc.. It is currently in Phase 2 development for Hypercholesterolemia.

AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor, and atorvastatin is a HMG-CoA reductase inhibitor.

AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor, and atorvastatin is a HMG-CoA reductase inhibitor. Used for Hypercholesterolemia.

At a glance

Generic name	AEGR-733 and atorvastatin
Sponsor	Aegerion Pharmaceuticals, Inc.
Drug class	MTP inhibitor, HMG-CoA reductase inhibitor
Target	MTP, HMG-CoA reductase
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

AEGR-733 works by inhibiting the microsomal triglyceride transfer protein (MTP), which is involved in the assembly and secretion of very-low-density lipoproteins (VLDL) from the liver. Atorvastatin, on the other hand, inhibits HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway. By inhibiting these enzymes, both drugs aim to lower cholesterol levels in the blood.

Approved indications

Hypercholesterolemia

Common side effects

Liver enzyme elevations
Musculoskeletal pain

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AEGR-733 and atorvastatin CI brief — competitive landscape report
AEGR-733 and atorvastatin updates RSS · CI watch RSS
Aegerion Pharmaceuticals, Inc. portfolio CI

Frequently asked questions about AEGR-733 and atorvastatin

What is AEGR-733 and atorvastatin?

AEGR-733 and atorvastatin is a MTP inhibitor, HMG-CoA reductase inhibitor drug developed by Aegerion Pharmaceuticals, Inc., indicated for Hypercholesterolemia.

How does AEGR-733 and atorvastatin work?

AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor, and atorvastatin is a HMG-CoA reductase inhibitor.

What is AEGR-733 and atorvastatin used for?

AEGR-733 and atorvastatin is indicated for Hypercholesterolemia.

Who makes AEGR-733 and atorvastatin?

AEGR-733 and atorvastatin is developed by Aegerion Pharmaceuticals, Inc. (see full Aegerion Pharmaceuticals, Inc. pipeline at /company/aegerion-pharmaceuticals-inc).

What drug class is AEGR-733 and atorvastatin in?

AEGR-733 and atorvastatin belongs to the MTP inhibitor, HMG-CoA reductase inhibitor class. See all MTP inhibitor, HMG-CoA reductase inhibitor drugs at /class/mtp-inhibitor-hmg-coa-reductase-inhibitor.

What development phase is AEGR-733 and atorvastatin in?

AEGR-733 and atorvastatin is in Phase 2.

What are the side effects of AEGR-733 and atorvastatin?

Common side effects of AEGR-733 and atorvastatin include Liver enzyme elevations, Musculoskeletal pain.

What does AEGR-733 and atorvastatin target?

AEGR-733 and atorvastatin targets MTP, HMG-CoA reductase and is a MTP inhibitor, HMG-CoA reductase inhibitor.

Drug class: All MTP inhibitor, HMG-CoA reductase inhibitor drugs
Target: All drugs targeting MTP, HMG-CoA reductase
Manufacturer: Aegerion Pharmaceuticals, Inc. — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Hypercholesterolemia
Compare: AEGR-733 and atorvastatin vs similar drugs
Pricing: AEGR-733 and atorvastatin cost, discount & access